272 related articles for article (PubMed ID: 1355764)
1. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
Hamori M; Zwirner M; Clédon P; Tinneberg HR
Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
[TBL] [Abstract][Full Text] [Related]
2. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
[TBL] [Abstract][Full Text] [Related]
3. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
[TBL] [Abstract][Full Text] [Related]
4. Induction of ovulation in polycystic ovary: human menopausal gonadotropin or human urinary follicle stimulating hormone?
Venturoli S; Paradisi R; Fabbri R; Porcu E; Orsini LF; Flamigni C
Int J Fertil; 1987; 32(1):66-70. PubMed ID: 2880819
[TBL] [Abstract][Full Text] [Related]
5. Ovulatory disorders in women with polycystic ovary syndrome.
Franks S; Adams J; Mason H; Polson D
Clin Obstet Gynaecol; 1985 Sep; 12(3):605-32. PubMed ID: 3933879
[TBL] [Abstract][Full Text] [Related]
6. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
[TBL] [Abstract][Full Text] [Related]
7. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
Smitz J; Andersen AN; Devroey P; Arce JC;
Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
[TBL] [Abstract][Full Text] [Related]
8. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
10. [Comparison between purified FSH and hMG for induction of ovulation in women with PCO syndrome].
Uemura T; Yoshimura Y; Ishikawa M; Asukai K; Minaguchi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jul; 41(7):923-6. PubMed ID: 2507714
[No Abstract] [Full Text] [Related]
11. Androgenic response in anovulatory women during menotropins stimulation.
Skaf RA; Shelden R; Kemmann E
Obstet Gynecol; 1981 Dec; 58(6):714-9. PubMed ID: 6796920
[TBL] [Abstract][Full Text] [Related]
12. Pure FSH induces ovulation in polycystic ovary syndrome despite rising androgen levels.
Traub AI; McFaul PB; Sheridan B; Leslie H
Clin Reprod Fertil; 1987 Aug; 5(4):167-71. PubMed ID: 3130977
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
15. Ovarian response patterns to human menopausal gonadotropin in mixed hyperandrogenemia.
Hamori M; Török A; Zwirner M; Tinneberg HR
Acta Endocrinol (Copenh); 1990 Dec; 123(6):598-602. PubMed ID: 2149487
[TBL] [Abstract][Full Text] [Related]
16. Induction of ovulation with D-Trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease.
Ayalon D; Ben-David M; Wohl R; Jaffe R; Vagman I; Eckstein N; Limor R; Comaru-Schally AM; Schally AV
Gynecol Endocrinol; 1988 Dec; 2(4):319-30. PubMed ID: 2976573
[TBL] [Abstract][Full Text] [Related]
17. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
18. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
20. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome.
Dodson WC; Hughes CL; Whitesides DB; Haney AF
J Clin Endocrinol Metab; 1987 Jul; 65(1):95-100. PubMed ID: 2953752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
